GC503 / AstraZeneca - LARVOL DELTA

Gracell drops 3 CAR-T programs in hopes of speeding more advanced assets to the finish line (Fierce Pharma) - "Gracell Biotechnologies is shaving down its CAR-T pipeline, throwing several programs out the window in an effort to speed its most advanced programs to the finish line...GC019F, a CD19 program targeting advanced B-cell acute lymphoblastic leukemia, has been cut. The CAR-T was being assessed in a phase 1 clinical trial. The second program left behind is GC027, an allogenic CAR-T designed to treat relapsed or refractory T-cell acute lymphoblastic leukemia. Lastly, Gracell dropped GC503, a mesothelin program designed to treat solid tumors...The company hopes to instead focus on the dual-targeting therapy GC012F derived from the company’s FasTCAR-T autologous platform made for next-day manufacturing....After completing a $150 million private placement financing earlier this month, Gracell anticipates its current cash will stretch into the second half of 2026, Chief Financial Officer Kevin Xie, Ph.D., said on the earnings call."

Commercial • Discontinued • Pipeline update • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Gynecologic Cancers • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Solid Tumor • T Acute Lymphoblastic Leukemia

Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire) - "SMART CARTTM Platform: On track to commence patient enrollment in a China IIT for GC503 in mesothelin-positive solid tumors in 2022; Plan to commence a China IIT for GC506 in CLDN18.2-positive solid tumors."

New trial • Trial status • Oncology • Solid Tumor

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire) - "SMART CART^TM Platform: (i) On track to commence patient enrollment in a China IIT for GC503 in mesothelin-positive solid tumors including ovarian cancer in 2022; (ii) Plan to commence a China IIT for GC506 in CLDN18.2-positive solid tumors."

Enrollment status • New trial • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor